ACDM News Item

Recent update from the regulatory landscape in clinical data management

Date: August 3, 2026

Thank you to the Regulatory Considerations DMEG for sharing this update.

On July 15 the FDA’s CDER posted their 2026 guidance agenda. The FDA uses this agenda to tell industry what guidance they plan to publish in 2026.

One of these new guidance documents is: Computer Software Assurance for AI-Based Systems in Drug Manufacturing and Clinical Investigations; Supplemental Guidance.

This document appears to be a separate document from the current draft guidance titled: Considerations for the Use of Artificial Intelligence To Support Regulatory Decision-Making for Drug and Biological Products.

Some other planned guidance of interest to data managers include:

Engaging with FDA to Discuss the Use of Digital Health Technologies in Clinical Investigations of Drug and Biological Products

Master Protocols for Drug and Biological Product Development; Revised Draft4

Collection of Race and Ethnicity Data in Clinical Trials and Clinical Studies for FDA Regulated Medical Products; Revised Draft

The ACDM DMEG for Regulatory Considerations plans to review these guidance as they are posted to evaluate the impact on data management.

Please find a copy of the agenda here: https://acdmglobal.org/wp-content/uploads/2026/08/CDER-2026-Guidance-Agenda_07.2026.pdf

Explore More News

Regulatory Considerations DMEG Shares Update on ICH E6(R3) Training Modules Available

The ICH Working Groups and The ICH Training Associates have released two new training . . .

Recent update from the regulatory landscape in clinical data management

On 22 September, MHRA published a new set of inspection dossier documents specifically for . . .

Regulatory Considerations DMEG Update – August 2026

Please read the following update from the Regulatory Considerations DMEG: July and . . .

Get to know ACDM Board Member: Santosh Karthikeyan Viswanathan

We caught up with one of ACDM’s new Board Members, Santosh Karthikeyan Viswanathan, to . . .

Guidance on Decentralized Clinical Trials to be Reviewed by the ACDM RC DMEG

Health Canada (HC) continues to publish new guidelines to support their modernization of . . .

Regulatory Considerations DMEG to Review Health Canada’s Draft Guidance

Thank you to the Regulatory Considerations DMEG for sharing this update. Health Canada . . .

Recent update from the regulatory landscape in clinical data management

Thank you to the Regulatory Considerations DMEG for sharing this update. On July 15 the . . .

Regulatory Considerations DMEG Update – June 2026

Please read the following update from the Regulatory Considerations DMEG: Regulators have . . .

FDA Announces New Initiative for Real-Time Clinical Trials

The U.S. Food and Drug Administration (FDA) has announced a new initiative to support the . . .

Get to know ACDM Board Member Jennifer Duff

We caught up with one of ACDM’s new Board Members, Jennifer Duff, to learn more about her. . . .

Recent News in Regulatory Landscape

The ACDM Regulatory Considerations DMEG have kindly put together a short news piece . . .

Real-Time Clinical Data Flow: Why the FDA’s New Pilot Validates the Data Flow Modernization Agenda

Tamer Chowdhury, on behalf of ACDM Technology DMEG. On April 28, FDA Commissioner Dr. . . .